• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / U.S. Equity

Analyst Actions -- 11/14/2011

Here are today's top research calls.
By DAVID PELTIER Nov 14, 2011 | 08:27 AM EST
Stocks quotes in this article: TOL, QCOM, CAT, BSX, TSN, VLO, PFE, AMGN, DHI, AMZN, MSFT, RIMM, CRM, TJX, A, AMAT, HSY, GMCR

Alexion Pharmaceuticals target boosted at Oppenheimer

Shares of ALXN now seen reaching $75, according to Oppenheimer. Expect approval in STEC-HUS. Outperform rating.

 -----

Amazon.com estimates, target raised at JP Morgan

Shares of AMZN now seen reaching $250, according to JP Morgan. Estimates also increased, as Kindle Fire should drive growth over the coming quarters.

-----

Amgen downgraded at Leerink

AMGN was downgraded from Outperform to Market Perform, Leerink Swann said. Company lacks potential catalysts for 2012.

-----

Amylin Pharmaceuticals upgraded at Baird

AMLN was upgraded from Neutral to Outperform, Robert Baird said. $15 price target. Eli Lilly overhang has removed and Bydureon should receive FDA approval.

-----

Applied Materials estimates, target increased at UBS

Shares of AMAT now seen reaching $13, according to UBS.  Estimates also increased on strength at foundry.  Neutral rating.

-----

Agilent  numbers lowered at Jefferies

Shares of A now seen reaching $60, according to Jefferies. Estimates also lowered, on lower cash forecasts. Buy rating.

-----

Boston Scientific estimates cut at Morgan Stanley

BSX estimates were reduced through 2013, Morgan Stanley said. Consensus expectations appear too high. Equal-weight rating.

-----

Caterpillar placed on Conviction Buy List at Goldman

CAT was added to the Conviction Buy list, Goldman Sachs said. $118 price target.  Incremental margin growth should accelerate in the coming quarters.

-----

CTrip.com downgraded at Brean

CTRP was downgraded from Buy to Hold, Brean Murray said. Offline growth is hurting margins.

----- 

Cullen/Frost Bankers, Inc estimates raised at Jefferies

CFR estimates were raised through 2012, Jefferies said. Following recently reported earnings. Hold rating.

-----

Dollar Tree numbers raised at Jefferies

Shares of DLTR now seen reaching $88, according to Jefferies. Estimates also raised, on EBIT margin expansion and its defensive profile. Buy rating.

-----

DR Horton downgraded at Guggenheim

DHI was downgraded from Buy to Neutral, Guggenheim said. $13 price target. Gross margin may remain weak for several quarters.

-----

DSW Inc. downgraded at Citigroup

DSW was downgraded from Buy to Neutral, Citigroup said.  $52 price target.  Expect slower growth over the next four quarters. 

-----

Eaton Vance downgraded at Citigroup

EV was downgraded from Neutral to Sell, Citigroup said.  $22 price target.  Clearly losing retail market share.

-----

Green Mountain Coffee downgraded at Argus

GMCR was downgraded from Buy to Hold, Argus Research said. Company appears to have lost its growth momentum.

----- 

Hershey Foods downgraded at Argus

HSY was downgraded from Buy to Hold, Argus Research said. Company may struggle to maintain recent growth momentum.

-----

Medical Properties Trust target raised at Jefferies

Shares of MPW now seen reaching $10.50, according to Jefferies. Growth aspect of MPW story continues to be attractive. Hold rating.

-----

Microsoft estimates reduced at Ticonderoga

MSFT estimates were cut through 2013, Ticonderoga Securities said. Company is facing higher costs.

-----

Pfizer downgraded at Leerink

PFE was downgraded from Outperform to Market Perform, Leerink Swann said. Company lacks near-term catalysts.

-----

Qualcomm target raised at Morgan Stanley       

Shares of QCOM now seen reaching $65, according to Morgan Stanley. Management will likely have an upbeat tone at the analyst meeting this week. Overweight rating.

-----

Questcor Pharmaceuticals numbers raised at Jefferies

Shares of QCOR now seen reaching $50, according to Jefferies. Estimates also raised, on sustained sales growth in NS. Buy rating.

-----

Research in Motion estimates lowered at UBS

RIMM estimates lowered through 2013, UBS said.  Earnings power remains elusive.  Maintain $26 price target and Neutral rating.

-----

salesforce.com (CRM) upgraded at Citigroup

CRM was upgraded from Neutral to Buy, Citigroup said.  $158 price target.  Increasing confidence in long term profitability potential.

-----

Spirit AeroSystems added to US 1 List at Bofa Merrill

SPR was added to the US 1 List, Bank of America Merrill Lynch said.  Expect company to generate positive FCF for the first time since 2005.  $26 price target and Buy rating. 

-----

Teekay estimates lowered at Credit Suisse

TK estimates were cut through 2012, Credit Suisse said. Company is buying back less stock. Outperform rating and $35 price target.

-----

TJX estimates raised at UBS

TJX estimates increased through 2013, UBS said.  SYMS bankruptcy an incremental opportunity for Northeast store growth. 

-----

Toll Brothers numbers increased at Goldman

TOL estimates were raised through 2013, Goldman Sachs said. Company recently boosted guidance. Buy rating and new $20 price target.

-----

TW Telecom upgraded at Morgan Stanley

TWTC was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is seeing solid sales growth, despite the macro environment. $22 price target.

-----

Tyson Foods upgraded at JP Morgan

TSN was upgraded from Neutral to Overweight, JP Morgan said. Stock has 40% upside potential from current levels.

 -----

Valero estimates upped at Oppenheimer

VLO estimates were boosted through 2012, Oppenheimer said. Company will likely buy back more shares with free cash flow. Outperform rating.

-----

Veeco Instruments estimates lowered at Citigroup

VECO estimates lowered through 2012, Citigroup said.  Expiring subsidies, significant oversupply, weak demand, and elevated inventory.  Maintain $27 price target and Neutral rating.

-----

WMS Industries numbers reduced at Goldman

Shares of WMS now seen reaching $21, according to Morgan Stanley. Estimates also cut, as the company is seeing slower growth across the board.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity

More from U.S. Equity

Zero-Covid? NATO's China Challenge, Quarter-End Volume, Yields, Trading Chevron

Stephen Guilfoyle
Jun 28, 2022 7:23 AM EDT

There was a time when Covid vaccine news was headline material. Not now, though, and this news could matter.

Kass: Why Markets Could Make a Yankees-Like Comeback

Doug Kass
Jun 27, 2022 2:00 PM EDT

I remain uncharacteristically bullish. Here's why.

Why I Just Can't Be More Positive About Stocks Right Now

James "Rev Shark" DePorre
Jun 27, 2022 11:13 AM EDT

Remember that countertrend bounce in May?

Indexes Break Resistance as Market Prospects Improve

Guy Ortmann
Jun 27, 2022 10:42 AM EDT

Friday's robust gains on heavy volume were helpful from a technical view.

The Fed Blinked and So Did We

Peter Tchir
Jun 27, 2022 9:30 AM EDT

Here's what we need to get a bigger rally.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login